Uses of Sphingosine-1-Phosphate Receptor Agonists

Abstract

The present invention relates to the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof for the prevention or treatment of atopic dermatitis.

Description

[Technical field]

[0001] The present invention relates to a compound represented by the following formula (1) for preventing or treating atopic dermatitis: [ka] (wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein) or a pharma- ceutically acceptable salt thereof. [Background technology]

[0002] Sphingosine-1-phosphate (S1P) is generated via the intracellular ceramide pathway, starting from ceramide. Ceramide is generated via two pathways, the first being the de novo biosynthetic pathway. Ceramide is also generated intracellularly by the degradation of sphingomyelin, a cell membrane component. S1P levels in each tissue are regulated by two biosynthetic sphingosine kinases (SphKs) and two biodegradative S1P phosphatases (S1P lyase and lysophospholipid phosphatase). S1P, generated via phosphorylation of sphingosine by sphingosine kinases, is known to mediate various cellular responses, such as cell proliferation, cytoskeletal organization and migration, adhesion- and tight junction assembly, and morphogenesis. S1P exists in plasma bound to plasma proteins including albumin at high concentrations (100-1000 nM), but exists in tissues at low concentrations.

[0003] S1P binds to the S1P receptor, a G-protein-coupled receptor, and exhibits various biological functions. Five subtypes of S1P receptors, S1P1 to S1P5, are known to date, and are named endothelial differentiation gene (EDG) receptors 1, 5, 3, 6, and 8, respectively. S1P receptors are known to be involved in various biological functions, such as leukocyte recirculation, neural cell proliferation, morphological changes, migration, endothelial function, vasoregulation, and cardiovascular development.

[0004] In recent years, many studies have revealed that S1P signaling processes via these receptors play an important role in a series of reactions associated with multiple sclerosis, such as inflammatory responses and repair processes, and nonselective S1P1 agonists have actually been approved as therapeutic agents for multiple sclerosis. S1P receptors are widely expressed in many cells related to the induction of multiple sclerosis. In particular, S1P1 receptors play an important role in the immune system. S1P1 receptors are mainly expressed on the surface of lymphocytes, such as T cells and B cells, and react with S1P to participate in the recirculation of lymphocytes. Under normal conditions, the concentration of S1P is higher in body fluids than in lymphatic tissues, so lymphocytes leave lymphatic tissues due to the difference in S1P concentration and circulate along the efferent lymph. However, down-regulation of lymphocyte S1P1 receptors by S1P1 agonists prevents lymphocyte egress from lymphoid tissues and reduces the infiltration of autoaggressive lymphocytes that cause inflammation and tissue damage in the central nervous system (CNS). This results in a therapeutic effect against multiple sclerosis. Fingolimod, a nonselective S1P1 agonist, has been approved as an oral agent for the treatment of multiple sclerosis. Binding to and activation of the S1P1 receptor paradoxically leads to internalization or degradation of the receptor from the lymphocyte surface, acting as a functional S1P1 antagonist.

[0005] Regarding such S1P receptors, Patent Document 1 (WO 2014 / 129796 (Publication date: August 28, 2014) discloses compounds that are effective as S1P receptor agonists.

[0006] Meanwhile, atopic dermatitis is a chronic recurrent skin eczema disease, and although the cause has not been clearly elucidated until now, it has been reported that immune-related factors overreact due to the action of external antigens. The drugs used for atopic dermatitis are mainly immunosuppressants, topical steroid preparations, antihistamines, etc. However, the use of these drugs has side effects and limitations in improving atopic dermatitis. As a result, there is a continuing need for new drugs that can more effectively prevent or treat atopic dermatitis. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] WO 2014 / 129796 Summary of the Invention [Problem to be solved by the invention]

[0008] The object of the present invention is to provide a compound represented by the following formula (1) for preventing or treating atopic dermatitis: [ka] (wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein) or a pharma- ceutically acceptable salt thereof. [Means for solving the problem]

[0009] The present invention relates to a method for the preparation of a pharmaceutical composition comprising administering to a patient a therapeutically effective amount of a compound represented by the [ka] [Wherein, X is carbon or nitrogen; R1 is hydrogen or alkyl; R2 is hydrogen, alkyl, halogen, CN, CF3 or COCF3; R3 and R4 are each independently hydrogen, alkyl, halogen, haloalkyl, or alkoxyalkyl; R5 is hydrogen, alkyl or halogen; R6 is, [ka] (wherein R7 is hydrogen or alkyl, and m and n are each independently 0, 1, 2, or 3.) or a pharma- ceutically acceptable salt thereof.

[0010] The present invention also provides a pharmaceutical composition for preventing or treating atopic dermatitis, comprising a therapeutically effective amount of the compound of formula (1) or a pharma- ceutical acceptable salt thereof together with a pharma- ceutical acceptable carrier.

[0011] Furthermore, the present invention provides a method for preventing or treating atopic dermatitis, comprising administering a therapeutically effective amount of the compound of formula (1) or a pharma- ceutically acceptable salt thereof to a subject in need thereof.

[0012] The present invention also provides use of the compound of formula (1) or a pharma- ceutically acceptable salt thereof for preventing or treating atopic dermatitis.

[0013] The present invention will be described in detail below.

[0014] According to one aspect of the present invention, there is provided a pharmaceutical agent for preventing or treating atopic dermatitis, comprising a therapeutically effective amount of the compound of formula (1) or a pharma- ceutical acceptable salt thereof.

[0015] According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating atopic dermatitis, comprising a therapeutically effective amount of the compound of formula (1) or a pharma- ceutical acceptable salt thereof, and further comprising a pharma- ceutical acceptable carrier.

[0016] The method for preparing the compound of formula (1) is described in detail in International Publication No. WO2014 / 129796A1, which is incorporated herein by reference.

[0017] In one embodiment of the present invention, in the formula (1), X is CH or N; R1 is hydrogen or C1-C5 alkyl; R2 is hydrogen, C1-C5 alkyl, halogen, CN, CF3 or COCF3; R3 and R4 are each independently hydrogen, C1-C5 alkyl, halogen, halo-C1-C5 alkyl, or C1-C5 alkoxy-C1-C5 alkyl; R5 is hydrogen, C1-C5 alkyl or halogen; R6 is, [ka] (wherein R7 is hydrogen or C1-C5 alkyl, and m and n are each independently 0, 1, 2, or 3.)

[0018] In another embodiment of the present invention, the compound of formula (1) is represented by the following formula (2): [ka] The compound is 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid represented by the formula:

[0019] In another embodiment according to the invention, the pharma- ceutically acceptable salts include, but are not limited to, acid addition salts formed with acids which form non-toxic acid addition salts containing pharma- ceutically acceptable anions, such as inorganic acids, such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and the like; organic carboxylic acids, such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, and the like; sulfonic acids, such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, or naphthalenesulfonic acid, and the like.

[0020] In another embodiment according to the present invention, a "therapeutically effective amount" for an individual subject means an amount sufficient to achieve the above-mentioned pharmacological effect, i.e., the above-mentioned therapeutic effect. The amount of the compound may vary depending on the condition and severity of the subject, the mode of administration, and the age of the subject to be treated, but can be determined by a person skilled in the art based on his / her knowledge.

[0021] In another embodiment according to the present invention, the therapeutically effective dose of the compound of formula (1) is, for example, usually in the range of about 0.1 to 500 mg per day depending on the frequency and intensity of administration. A typical daily dose for intramuscular or intravenous administration to an adult is in the range of about 0.1 to 300 mg per day, which can be administered in divided unit doses. Some patients may require a higher daily dose.

[0022] In the present invention, the "pharmaceutical composition" may contain other ingredients such as carriers, diluents, excipients, etc., in addition to the active ingredient of the present invention. Thus, the pharmaceutical composition may contain a pharma- ceutically acceptable carrier, diluent, excipient, or a combination thereof, as necessary. The pharmaceutical composition facilitates administration of the active compound to the body. Various methods for administering the compound include, but are not limited to, oral, injection, aerosol, parenteral, and topical administration.

[0023] As used herein, the term "carrier" refers to a compound that facilitates the introduction of a compound into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a conventional carrier that facilitates the introduction of many organic compounds into living cells or tissues.

[0024] As used herein, "diluent" refers to a compound that is diluted in a solvent that dissolves the compound as well as stabilizing the biologically active form. In the art, salts dissolved in buffer solutions are used as diluents. The conventionally used buffer solution is phosphate buffered saline, which mimics the salt forms in body fluids. The buffer diluent does not significantly change the biological activity of the compound, since the buffer solution can control the pH of the solution at low concentrations.

[0025] As used herein, the term "pharmaceutical acceptable" refers to a property that does not impair the biological activity and physical properties of a compound.

[0026] The compound of the present invention can be formulated into various pharmaceutical dosage forms.When preparing the pharmaceutical composition according to the present invention, the active ingredient, specifically, the compound of formula (1) or its pharma- ceutically acceptable salt, is mixed with a pharma- ceutically acceptable carrier selected in consideration of the dosage form to be prepared.For example, the pharmaceutical composition according to the present invention can be formulated into injections, oral preparations, etc., as necessary.

[0027] The compounds of the present invention can be formulated in a conventional manner using known pharmaceutical carriers and excipients, and filled into unit dose forms or multi-dose containers. The formulation may be in the form of a solution, suspension, or emulsion in an oily or aqueous solvent, and may contain conventional dispersing, suspending, or stabilizing agents. The compounds may also be in the form of a dry powder, which is dissolved, for example, in sterilized pyrogen-free water before use. The compounds of the present invention can also be formulated into suppositories by using conventional suppository bases, such as cocoa butter or other glycerides. Solid forms for oral administration include capsules, tablets, pills, powders, and granules. Capsules and tablets are particularly preferred. Tablets and pills are preferably enteric coated. The solid forms can be prepared by mixing the compounds of the present invention with at least one carrier selected from one or more inert diluents, such as sucrose, lactose, starch, and lubricants, disintegrants, binders, and the like, such as magnesium stearate. The compounds can also be formulated as transdermal dosage forms, for example, lotions, ointments, gels, creams, patches, or sprays.

[0028] As used herein, "prevention" refers to reducing or eliminating the chance of contracting a disease.

[0029] "Treatment" is used herein to mean arresting, slowing or ameliorating the progression of a disease in a subject who exhibits symptoms of the disease. Effect of the Invention

[0030] The medicament or pharmaceutical composition according to the present invention can effectively prevent or treat atopic dermatitis. [Brief description of the drawings]

[0031] [Figure 1] FIG. 1 is a schematic diagram showing the induction process of an animal model of atopic dermatitis. [Diagram 2] 1 shows the results of measuring the reduction in ear thickness after administration of a test substance to an animal model of atopic dermatitis. [Diagram 3] 1 shows the results of measuring the reduction in ear weight after administration of a test substance to an animal model of atopic dermatitis. [Figure 4] This shows the results of measuring the decrease in blood IgE levels after administering a test substance to an animal model of atopic dermatitis. [Diagram 5] 1 shows the results of measuring the reduction in epithelial thickness after administration of a test substance to an animal model of atopic dermatitis. [Figure 6] 1 shows the results of measuring the reduction in mast cell accumulation following administration of a test substance to an animal model of atopic dermatitis. [Figure 7] The results are measured in comparison with the control substance etrasimod in an animal model of atopic dermatitis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] The present invention will now be described in detail with reference to examples. However, it should be understood that the scope of protection of the present invention is not limited to these examples.

[0033] Preparation Example: Synthesis of 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid (hereinafter referred to as "test compound") was prepared according to the method described in Example 153 of International Publication No. WO2014 / 129796 A1.

[0034] Example 1: Induction of an animal model of atopic dermatitis Atopic dermatitis animal model was induced in mice (Balb / c) using oxazolone. The first sensitization day of oxazolone was set as day 0, and oxazolone was administered orally or percutaneously once a day from the 7th day. When the oxazolone application day and the drug administration day overlapped, the drug was administered approximately 6 hours after oxazolone application.

[0035] The abdominal hair of all mice was removed 1 day before the first application of oxazolone. Then, 1% or 0.2% oxazolone was prepared using a 4:1 ratio of acetone / corn oil, and the same doses and schedules of induction and reduction were performed on the abdomen and both ears of the shaved mice, as shown in Table 1 and Figure 1.

[0036] [Table 1]

[0037] Example 2: Preparation of Orally Administered Substances Test substances (test compounds and dexamethasone as a positive control) were prepared for each dose using 0.5% methylcellulose as shown in Table 2 below. In the case of test compounds, the HCl salt form was taken into consideration. Test substances were dissolved in 0.5% methylcellulose and sonicated. If they were not completely dissolved, they were administered in suspension.

[0038] Example 3: Preparation of Substances for Transdermal (Topical) Administration The test substance was prepared by dissolving it in a solution (PEG400:100% ethanol = 1:1) at a concentration of 0.1% (w / v). 5 mL of PEG400 was added to 10 mg of the test substance and sonicated. After it was dissolved to some extent, 5 mL of 100% ethanol was added and sonicated to completely dissolve it. In addition, the vehicle and the test substance were prepared fresh every day and used.

[0039] [Table 2]

[0040] Example 4: Measurement results The reduction in ear thickness was measured on the 14th and 21st days after administration of the test substance, and the results are shown in Table 3 and Figure 2. On the 21st day after administration of the test substance, the reduction in ear weight was measured after necropsy, and the results are shown in Table 3 and Figure 3. On the 21st day after administration of the test substance, the reduction in blood IgE concentration was measured, and the results are shown in Table 3 and Figure 4. In addition, the reduction in epithelial thickness and the accumulation of mast cells in the ear tissue were measured on the 21st day after administration of the test substance, and the results are shown in Table 3, Figure 5, and Figure 6.

[0041] [Table 3]

[0042] As can be seen from Table 3 and Figures 2 to 6, the test compound showed a dose-dependently superior effect compared to dexamethasone (positive control) in the oxazolone-induced atopic dermatitis animal model. From these results, it was confirmed that the compound of the present invention can be used as a preventive or therapeutic agent for atopic dermatitis.

[0043] Example 5: Comparative Experiment For comparison with another S1P receptor agonist, etrasimod (2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid), the reduction in ear thickness, reduction in ear weight, blood IgE concentration, reduction in epithelial thickness of ear tissue, and mast cell accumulation were measured in the same manner as in Example 4, and the results are shown in Table 4 and FIG. 7.

[0044] [Table 4]

[0045] As can be seen from Table 4 and Figure 7, the test compounds showed equal or superior efficacy at lower doses compared to the control substance, etrasimod. From these results, it is expected that side effects due to systemic exposure can be minimized by administering the same amount to obtain better efficacy or by administering a lower dose to achieve a certain level of efficacy. In addition, since the compound has low affinity with GIRKs (G protein-coupled inward rectifier potassium channels), which induce brachycardia by S1P receptor agonists, the significance of side effects can be expected.

Claims

1. A therapeutically effective amount of the following formula (1) 【Chemistry 1】 wherein X is carbon or nitrogen; R is hydrogen or alkyl; R2 is hydrogen, alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, alkyl, halogen, haloalkyl, or alkoxyalkyl; R5 is hydrogen, alkyl or halogen; R6 is, 【Chemistry 2】 (wherein R7 is hydrogen or alkyl, and m and n are each independently 0, 1, 2, or 3.) or a pharma- ceutical acceptable salt thereof.

2. X is CH or N; R is hydrogen or C 1 -C 5 is alkyl; R2 is hydrogen, C 1 -C 5 Alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, C 1 -C 5 Alkyl, halogen, halo-C 1 -C 5 Alkyl or C 1 -C 5 Alkoxy-C 1 -C 5 is alkyl; R5 is hydrogen, C 1 -C 5 is alkyl or halogen; R6 is, 【Chemistry 3】 (wherein R7 is hydrogen or C 1 -C 5 2. The drug for preventing or treating atopic dermatitis according to claim 1 , wherein m is alkyl, and m and n are each independently 0, 1, 2 or 3.

3. The compound of the formula (1) is represented by the following formula (2): 【Chemistry 4】 2. The agent for preventing or treating atopic dermatitis according to claim 1, which is 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid represented by the formula:

4. The agent for preventing or treating atopic dermatitis according to claim 1, wherein the pharma- ceutically acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid.

5. A therapeutically effective amount of the following formula (1) 【Chemistry 5】 wherein X is carbon or nitrogen; R is hydrogen or alkyl; R2 is hydrogen, alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, alkyl, halogen, haloalkyl, or alkoxyalkyl; R5 is hydrogen, alkyl or halogen; R6 is, 【Chemistry 6】 (wherein R7 is hydrogen or alkyl, and m and n are each independently 0, 1, 2, or 3.) or a pharma- ceutical acceptable salt thereof, further comprising a pharma- ceutical composition for preventing or treating atopic dermatitis, the pharmaceutical composition comprising a compound represented by the formula:

6. X is CH or N; R is hydrogen or C 1 -C 5 is alkyl; R2 is hydrogen, C 1 -C 5 Alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, C 1 -C 5 Alkyl, halogen, halo-C 1 -C 5 Alkyl or C 1 -C 5 alkoxy-C1-C5 alkyl; R5 is hydrogen, C 1 -C 5 is alkyl or halogen; R6 is, 【Chemistry 7】 (wherein R7 is hydrogen or C 1 -C 5 6. The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 5, wherein m is alkyl, and m and n are each independently 0, 1, 2 or 3.

7. The compound of the formula (1) is represented by the following formula (2): 【Chemistry 8】 The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 5, wherein the compound is 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid represented by the formula:

8. 6. The pharmaceutical composition for preventing or treating atopic dermatitis according to claim 5, wherein the pharma- ceutical acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid.

9. A therapeutically effective amount of the following formula (1) 【Chemistry 9】 wherein X is carbon or nitrogen; R is hydrogen or alkyl; R2 is hydrogen, alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, alkyl, halogen, haloalkyl, or alkoxyalkyl; R5 is hydrogen, alkyl or halogen; R6 is, 【Chemistry 10】 (wherein R7 is hydrogen or alkyl, and m and n are each independently 0, 1, 2, or 3) or a pharma- ceutically acceptable salt thereof for use in a method for preventing or treating atopic dermatitis.

10. For the production of a medicament for the prevention or treatment of atopic dermatitis, 【Chemistry 11】 wherein X is carbon or nitrogen; R is hydrogen or alkyl; R2 is hydrogen, alkyl, halogen, CN, CF 3 or COCF 3 and R and R are each independently hydrogen, alkyl, halogen, haloalkyl, or alkoxyalkyl; R5 is hydrogen, alkyl or halogen; R6 is, 【Chemistry 12】 (wherein R7 is hydrogen or alkyl, and m and n are each independently 0, 1, 2 or 3) or a pharma- ceutically acceptable salt thereof.

Images